

# Treatment of Lesions With a High Risk of Stenosis. Comparative Study in 300 Patients of Rapamycin- and Paclitaxel-Eluting Polymer-Based Stents, and Bare Metal Stents

José M. de la Torre Hernández, Fermín Sainz Laso, Cristina Ruisánchez, Javier Zueco, Álvaro Figueroa, and Thierry Colman

Unidad de Hemodinámica y Cardiología Intervencionista, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain.

**Introduction and objectives.** Rapamycin- and taxol-eluting stents have been shown to reduce restenosis, but there are no large-scale studies of their usefulness in lesions with a high risk of restenosis, or of the relative merits of the 2 devices. This prospective study compared their safety and efficacy in lesions with a high risk of restenosis.

**Patients and method.** We included consecutive patients with lesions to treat that met at least one of the following criteria: a) in-stent restenosis; b) diffuse ( $>20$  mm) restenosis; c) small vessel ( $\leq 2,5$  mm) restenosis; or d) total occlusion. Patients received different devices along three consecutive study periods: bare metal (conventional) stents, sirolimus-eluting (rapamycin) stents, and paclitaxel-eluting (taxol) stents.

**Results.** One hundred patients in each group were included, for a total of 300 patients. In the sirolimus group, after  $8.5 \pm 2$  months of follow-up, there were 2 late thromboses (2%) and only 1 patient (1%) required target lesion revascularization. In the paclitaxel group 2 patients (2%) had in-hospital stent thrombosis (1 acute, 1 subacute), and after  $9 \pm 2.5$  months of follow-up only 1 patient (1%) needed target lesion revascularization. In the conventional group, after  $8 \pm 2$  months of follow-up, there was 1 subacute thrombosis (1%) and 15 patients (15%) had clinical restenosis requiring target lesion revascularization. Event-free survival curves were significantly better with drug-eluting stents ( $P < .01$  vs conventional stents).

**Conclusion.** Rapamycin- and taxol-eluting stents were safe for lesions with a high risk of restenosis. These stents were associated with a lower rate of target lesion revascularization during follow-up compared to bare metal stents.

**Key words:** Coronary lesion. Stent. Restenosis.

Correspondence: Dr. J.M. de la Torre Hernández.  
Unidad de Hemodinámica y Cardiología Intervencionista.  
Hospital Universitario Marqués de Valdecilla.  
Avda. Valdecilla, s/n. 39008 Santander. Cantabria. España.  
E-mail: hemodinamica@humv.es

Received July 12, 2004.

Accepted for publication December 14, 2004.

**Tratamiento de lesiones con alto riesgo de reestenosis. Estudio comparativo en 300 pacientes del stent liberador de rapamicina, el stent con polímero liberador de paclitaxel y el stent convencional**

**Introducción y objetivos.** Se ha demostrado que los stents con rapamicina y paclitaxel reducen la reestenosis, pero no hay estudios amplios en contextos lesionales de alto riesgo ni estudios que comparen la eficacia de ambos. En este estudio prospectivo nos planteamos comparar su eficacia en lesiones de alto riesgo reestenótico.

**Pacientes y método.** Se incluyó a pacientes consecutivos con angioplastia sobre lesiones de las cuales alguna reuniera al menos una de las siguientes características: a) reestenosis intra-stent; b) difusa ( $> 20$  mm); c) vaso pequeño ( $\leq 2,5$  mm), y d) oclusión total. Los pacientes fueron tratados de forma distinta, en 3 períodos consecutivos, mediante stent convencional, stent de rapamicina y stent de taxol.

**Resultados.** Se ha incluido a 300 pacientes, 100 en cada grupo. En el grupo de stents de rapamicina, con un seguimiento de  $8,5 \pm 2$  meses, se produjeron 2 (2%) trombosis tardías y un (1%) caso de revascularización de la lesión tratada. En el grupo de stents de taxol se produjeron 2 (2%) trombosis (aguda y subaguda) en el hospital, y en un seguimiento de  $9 \pm 2,5$  meses ocurrió 1 muerte no cardíaca (1%) y 1 paciente (1%) fue revascularizado en la lesión tratada. En el grupo de stents convencionales, con un seguimiento de  $8 \pm 2$  meses, hubo 1 trombosis subaguda (1%) y 15 casos de reestenosis clínica con revascularización (15%). Las curvas de supervivencia libre de eventos fueron significativamente mejores con los stents recubiertos ( $p < 0,01$  en comparación con el convencional).

**Conclusión.** La utilización de stents con rapamicina y paclitaxel en lesiones de alto riesgo para reestenosis fue segura, y la necesidad de una nueva revascularización durante el seguimiento fue comparablemente baja con ambos en relación con la del stent convencional.

**Palabras clave:** Lesión coronaria. Stent. Reestenosis.

**ABBREVIATIONS**

RES: rapamycin-eluting stents.

PES: paclitaxel-eluting stents.

PTCA: percutaneous transluminal coronary angioplasty.

ECG: electrocardiogram.

**INTRODUCTION**

One of the main challenges in percutaneous coronary intervention is to limit the rate of restenosis and the subsequent need for revascularization of the vessel. When multivessel percutaneous revascularization is compared with coronary artery bypass surgery, the need for further revascularization accounts for the most of the difference in the rate of events between the two approaches during follow-up.<sup>1</sup> The studies that have been performed so far with drug-eluting stents (paclitaxel and rapamycin) have shown a substantial decrease in restenosis and subsequent need for further revascularization in previously treated lesions.<sup>2-7</sup> Nevertheless, these large studies did not include patients who were at higher risk of restenosis with bare metal stents, such as those with total occlusions, in-stent restenosis, very long lesions (>30 mm) or those in vessels less than or equal to 2.5 mm. Studies of small retrospective series of patients with such lesions have been published in which different models of drug-eluting stent were used and in which some very promising results were obtained.<sup>8-16</sup>

Similarly, no studies have been performed that compare the efficacy and safety of the 2 stents. If there were some difference between the 2 stents, this could be detected more easily in patients with more complex lesions. Thus, in the present study, we compared the clinical course of 2 groups of patient with a similar complex lesion profile treated with paclitaxel-eluting stents (PES) or rapamycin-eluting stents (RES). As a control, we included a third comparable group treated with bare metal stents (comprising our experience with patients treated immediately prior to the introduction of drug-eluting stents).

**PATIENTS AND METHODS**

We included patients referred to our unit with the clinical indications for coronary angiography who were candidates for percutaneous revascularization and whose lesions (all or at least one) met at least one of the following criteria:

1. In-stent restenosis.
2. Total occlusion however long it has been present.

3. Diffuse lesion (>20 mm).
4. Small vessel lesion ( $\leq 2.5$  mm).

Treatment periods:

1. From October 2001 to May 2002, the patients were treated with bare metal stents.

2. From June to December 2002, 72% of the lesions that met at least one of the above criteria were treated with RES, Cypher®. The remaining lesions were treated with bare metal stents, whether because RES of the appropriate size were not available or because the lesion profile was more favorable (focal lesions in 2.5 mm vessels or diffuse lesions of 20-25 mm in vessels  $\geq 3$  mm). All total occlusions and in-stent restenoses were treated with RES.

3. From April to December 2003, 70% of the lesions that met at least one of the above criteria were treated with PES, Taxus®. The remaining lesions were treated with bare metal stents (on specific occasions) or with RES due to the availability of stents of the appropriate size or because a member of the team used RES more often (for purely logistic reasons).

For each period, the first 100 consecutive cases treated with the corresponding stent were included. The results of the series of patients treated with RES alone have already been published separately in this journal.<sup>16</sup>

Patients who underwent primary angioplasty and those who were in cardiogenic shock were excluded. Patients with occlusions were only included if stent placement was possible. Whether the stent was implanted directly or not was left to the discretion of the surgeon, though direct placement was not attempted in any of the patients with complete occlusion, those needing a long stent (>23-24 mm) and when vessel calcification or marked bending or twisting was evident. Digital quantitative coronary angiography was done after the procedure.

The femoral approach was used for implantation and, in all cases, vascular closure devices were used. The use of glycoprotein IIb/IIIa inhibitors was left to the discretion of the surgeon. Angiographic success was defined as residual stenosis less than 25% with TIMI flow III. Enzyme measurements were only done in patients in whom there was clinical or electrocardiographic suspicion of necrosis after the percutaneous transluminal coronary angioplasty (PTCA) (procedural complication, ischemia and/or post-PTCA symptoms). All patients received an oral dose of 300 mg of clopidogrel immediately after the procedure, and subsequently a combination of 100 mg of aspirin and 75 mg of clopidogrel for 3 months in the case of RES and 6 months in the case of PES.

Clinical follow-up consisted of a clinical visit 6 to 12 months after the procedure and, an additional telephone call in which the investigator spoke directly with

the patient. To compare the clinical course of the 3 consecutive series, we finished follow-up of each group when the last patient had been followed for 6 months. Thus, the length of follow-up was similar in the 3 groups (mean, 8-9 months; range, 6-12 months). Patients were assessed by their corresponding clinical cardiologists, who indicated tests for ischemia or coronary angiography as they saw fit. Events were classified as:

1. Death (cardiac or noncardiac).
2. Q-wave myocardial infarction defined by the appearance of new Q-waves in the electrocardiogram (ECG), whether or not preceded by clinical symptoms, or non-Q-wave myocardial infarction defined as acute coronary syndrome associated with enzymatic elevation (more than twice the upper limit of normal for the creatine kinase MB isozyme [CK-MB]) without subsequent appearance of Q-waves in the ECG.
3. Stent thrombosis defined as angiographic observation of total or partial occlusion of the stent by thrombotic material preceded by acute clinical signs and symptoms with possible ST-segment elevation.
4. Revascularization, which may have been done in the treated lesion (due to in-stent restenosis) or in a new lesion.

## Statistical Analysis

Continuous variables were presented as means  $\pm$ SD. Categorical variables were expressed as percentages. The continuous variables were compared using the Student *t* test if the distribution was normal and using the Wilcoxon test if the distribution was not normal (according to the normal distribution test of Kolmogorov-Smirnov). Categorical variables were compared with the  $\chi^2$  test or the Fisher exact test, depending on which was appropriate. All variables were compared for the 2 groups of drug-eluting stent and for these groups and the control group. Kaplan-Meier event-free survival curves were obtained for each group and compared by the logrank test. Statistical significance was set at  $P < .05$ . The SPSS 11.0 statistical package was used.

## RESULTS

The first 100 consecutive patients from each treatment period with the corresponding type of stent were included. From October 2001 to May 2002, 100 patients with 170 lesions were treated with bare metal stents. Of these lesions, 117 (69%) met the selection criteria. From June to December 2002, 100 patients from the RES group were treated with Cypher® stents, corresponding to 154 lesions, of which 109 (71%) met the selection criteria. From April to December 2003, 100 patients from the PES group were treated with Ta-

TABLE 1. Clinical Characteristics of the 300 Patients\*

	RES (n=100)	PES (n=100)	BMS (n=100)
Age, years	61 $\pm$ 11	62.5 $\pm$ 10	62 $\pm$ 11
Men	84 (84%)	80 (80%)	77 (77%)
Diabetes	21 (21%)	28 (28%)	23 (23%)
Hypertension	53 (53%)	55 (55%)	52 (52%)
Prior infarction	57 (57%)	49 (49%)	47 (47%)
Prior angioplasty	31 (31%)	25 (25%)	27 (27%)
Prior surgery	11 (11%)	5 (5%)	2 (2%)†
Statins prior to the procedure	59 (59%)	68 (68%)	50 (50%)‡
Statins during follow-up	82 (82%)	84 (84%)	77 (77%)
Ejection fraction, %	51 $\pm$ 9	52 $\pm$ 10	51 $\pm$ 8
Unstable angina	51 (51%)	55 (55%)	49 (49%)
Stable angina	34 (34%)	40 (40%)	42 (42%)

\*BMS indicates bare metal stent; RES, rapamycin-eluting stent; PES, paclitaxel-eluting stent.

† $P < .05$  for comparison RES vs BMS.

‡ $P < .05$  for comparison PES vs BMS.

xus® stents, corresponding to 164 lesions, of which 118 (72%) met the selection criteria. Placement of drug-eluting stents was successful whenever the procedure was attempted.

The clinical characteristics of the 3 groups of patient are shown in Table 1. The only significant differences were seen in the rate of previous surgical bypass operations, which was higher in the RES group than in the group with bare metal stents, and in prior statin treatment. Statin treatment was more widespread in the PES group because statin use has increased over the study period (the PES group were the most recently treated patients). Nevertheless, treatment with statins during follow-up was very similar in both groups.

The angiographic characteristics of the lesions of each group are described in Table 2. In all groups, a similar proportion of lesions met the criteria outlined in the previous section (69% in the group with bare metal stents, 71% the RES group and 72% in the PES group). The distribution of type of lesion was comparable, although a trend toward a lower rate of in-stent restenosis requiring treatment was seen in the PES group. The characteristics of the procedure were likewise very similar, though worthy of mention is the trend toward longer total stent lengths per patient in the drug-eluting stent groups compared to the group with bare metal stents. This difference was significant for comparison of the PES group with the group who received bare metal stents (Table 3). The angiographic success was fully comparable among all 3 groups.

## Procedural and in-Hospital Complications

Two non-Q-wave myocardial infarctions occurred in the RES group (2%). One of these was due to an occlusive retrograde dissection after stent placement in

**TABLE 2. Angiographic Characteristics of the Target Lesions\***

	RES (n=154)	PES (n=164)	BMS (n=170)
Total occlusions	31 (20%)	28 (17%)	27 (16%)
In-stent restenosis	31 (20%)	20 (12%)	26 (15%)
Occlusive	7	2	3
Diffuse ( $\geq 10$ mm)	12	8	9
Focal ( $\leq 10$ mm)	12	10	14
Diffuse ( $>20$ mm)	52	(34%)	59 (36%)
51 (32%)			
Small vessel ( $\leq 2.5$ mm)	55 (36%)	60 (36.5%)	64 (40%)
Reference diameter, mm	2.6 $\pm$ 0.2	2.6 $\pm$ 0.3	2.54 $\pm$ 0.2
Lesion length, mm	19 $\pm$ 8	19 $\pm$ 8	18 $\pm$ 7
Baseline stenosis	69 $\pm$ 10%	67 $\pm$ 9%	66 $\pm$ 9%
Poststent stenosis	6 $\pm$ 3%	6 $\pm$ 3%	6.5 $\pm$ 3%
Left anterior descending artery	84 (54.5%)	88 (53.6%)	90 (53%)
Right coronary artery	39 (25%)	41 (25%)	39 (23%)
Circumflex artery	22 (14.3%)	32 (19.5%)	39 (23%)
Left coronary artery	5 (3.2)	2 (1.2%)	1 (0.6%)
Saphenous vein	2 (1.3%)	1 (0.6%)	1 (0.6%)
Mammary artery	2 (1.3%)	0	0

\*BMS indicates bare metal stent; RES, rapamycin-eluting stent; PES, paclitaxel-eluting stent.

**TABLE 3. Characteristics of the Procedure\***

	RES	PES	BMS
Target lesions/patient	1.54 $\pm$ 0.7	1.64 $\pm$ 0.8	1.7 $\pm$ 0.7
Stent length, mm	21 $\pm$ 8.5	21.5 $\pm$ 8	19.5 $\pm$ 8
Stent diameter, mm	2.74 $\pm$ 0.26	2.78 $\pm$ 0.4	2.66 $\pm$ 0.4
Total stent length/patient, mm	33 $\pm$ 16	34 $\pm$ 16	29 $\pm$ 17†
Direct stenting	34%	27%	33%
Abciximab	16%	14%	25%
Complete revascularization‡	67%	66%	62%
Procedural success	98%	98%	98%

\*BMS indicates bare metal stent; RES, rapamycin-eluting stent; PES, paclitaxel-eluting stent.

† $P < .05$  for comparison PES vs SC.

‡Anatomic (occlusion  $>50\%$  in vessels  $\geq 2$  mm).

the right medial coronary artery and resolved without additional further stenting. The other was due to untreatable occlusion of a small diagonal branch ( $<2$  mm diameter) after stenting of the left anterior descending artery. A transient ischemic attack occurred in 1 66-year-old male hypertensive patient (1%) (Table 4).

In the PES group, a non-Q-wave myocardial infarction due to lack of reperfusion was reported after stenting. Two patients suffered stent thrombosis which presented as ST-segment elevation myocardial infarction. In 1, who received a 2.5/8 mm stent within a stent due to distal restenosis of the left anterior descending artery, thrombosis occurred after 3 hours. In the other, who received a 2.57/32 mm stent implanted in the medial left anterior descending artery, thrombosis occurred 24 hours after the procedure. Neither pa-

**TABLE 4. Clinical Events During Follow-up\***

	RES (n=100)	PES (n=100)	BMS (n=100)
In-hospital			
Acute or subacute thrombosis	0	2 (2%)†	0
Non-Q-wave infarction	2 (2%)	1 (1%)	2 (2%)
Transient ischemic attack	1 (1%)	0	0
Clinical follow-up after discharge			
Death	0	1 (1%)‡	0
Nonfatal myocardial infarction	1 (1%)§	2 (2%)	2 (2%)
Subacute thrombosis	0	0	1 (1%)
Late thrombosis	2 (2%)	0	0
Repeat PTCA of restenosis	1 (1%)	1 (1%)	15 (15%)
Other lesion revascularization	1 (1%)	2 (2%)	3 (3%)
Stroke	1 (1%)	0	0

\*PTCA indicates percutaneous transluminal coronary angioplasty; BMS, bare metal stent; RES, rapamycin-eluting stent; PES, paclitaxel-eluting stent.

†Appeared as ST-segment elevation infarctions.

‡Noncardiac death (domestic accident).

§Corresponded to one of the late thromboses.

**TABLE 5. Revascularization for Restenosis According to Lesion Type\***

	RES	PES	BMS
Vessel $\leq 2.5$ mm	1/55 (1.8%)	0/60 (0%)	12/64 (18.7%)†
Diffuse lesion	2/52 (3.8%)	1/59 (1.7%)	10/51 (19.6%)‡
Occlusions	0/31 (0%)	0/28 (0%)	4/27 (14.8%)
In-stent restenosis	0/31 (0%)	0/20 (0%)	4/26 (15.4%)

\*BMS indicates bare metal stent; RES, rapamycin-eluting stent; PES, paclitaxel-eluting stent.

† $P < .01$  for comparison of RES and PES with BMS.

‡ $P < .05$  for comparison of RES and PES with BMS.


tient received abciximab during the procedure. In these cases, the distal bed was in poor condition and showed diffuse disease. A second percutaneous coronary intervention was performed with abciximab (thrombus aspiration and balloon dilatation), with a satisfactory outcome.

Two non-Q-wave myocardial infarctions were reported in the group with bare metal stents. These events were related to unresolved occlusion of 2 small diagonal branches ( $\leq 2$  mm) after treatment of side-branch occlusions.

## Clinical Follow-up

All patients in the RES and PES groups and 99% of the patients in the group with bare metal stenting underwent clinical follow-up.

In the RES group, no deaths occurred during 8.5 $\pm$ 2 months (range, 6-12 months) of follow-up and 2 patients (2%) had late thromboses, 1 of which led to Q-wave myocardial infarction (Table 4). Thrombosis occurred after 3.5 months in 1 patient with a 2.75/33 mm stent implanted to treat an occlusive and diffuse in-stent proximal restenosis of the left anterior des-



**Figure.** Kaplan-Meier event-free survival curves (all-cause mortality, infarction or revascularization) for the 3 groups: BMS (solid line), PES (dotted line), and RES (broken line).  $P=.002$  for comparison RES vs BMS and  $P=.004$  for the comparison PES vs BMS.

ending artery, with diffuse disease in a distal bed and extensive collateral circulation from the right coronary artery. Competitive flow from this collateral circulation was present even after stenting. The signs and symptoms of thrombosis were unstable angina but without enzymatic elevation due to the aforementioned collateral circulation. The second case occurred 7 months after placement of a 3/33 mm stent in a proximal *de novo* lesion of the left anterior descending artery, with 50% occlusion at a side branch. The patient with clinical restenosis requiring repeat PCTA had type-1 diabetes and severe, multivessel diffuse coronary artery disease and she had initially received 92 mm of stents in 3 vessels. Coronary angiography, done 5 months after the procedure because of recurrence of symptoms, showed 2 severe in-stent restenotic lesions, 1 in the left anterior descending artery and 1 in the circumflex artery, both of which were focal (<5 mm) and located away from the ends of the stent. During follow-up, 3 revascularization procedures (3%) were performed on a treated lesion, 2 of which corresponded to late thrombosis (Table 4). Another patient underwent angioplasty for a new lesion. At the end of follow-up, only 2 patients (2%) presented symptoms compatible with class II stable angina, but they were not referred for a further angiographic studies because their symptoms could be controlled satisfactorily by medical treatment.

In the PES group, with follow-up lasting  $9\pm2.5$  months (range, 6-14 months), 1 patient died of a non-cardiac cause (accidental fall). No new stent thrombo-

sis was reported and 2 patients presented non-Q-wave myocardial infarction (2%). One patient (1%) presented clinical restenosis that required percutaneous revascularization and 2 patients (those who had presented non-Q-wave myocardial infarctions) underwent revascularization of new lesions. In 1 of these patients, restenosis of the PES that bordered on angiographic significance (50%) was seen. The lesion was assessed with a pressure guide and a fraction flow reserve (FFR) of 0.85 was obtained, so other severe lesions in another vessel related to the clinical signs and symptoms were treated. At the end of follow-up, 3 patients (3%) had class II stable angina that was controlled with medical treatment and a further 3 had presented 1-2 episodes of brief self-limiting chest pain during the whole follow-up period. The only case of revascularization of a treated lesion corresponded to a patient who had received a 3/24 mm stent in the proximal left anterior descending artery without covering the ostium, which was not affected. After 11 months, a new catheterization procedure was performed for unstable angina and a severe lesion in the ostium of the left anterior descending artery was observed (within 5 mm of the end of the stent).

In the group treated with bare metal stents, with a follow-up of  $8\pm2$  months (range, 6-12 months), no deaths were reported and 1 subacute thrombosis occurred (1%), but there were no late thromboses. Two Q-wave myocardial infarctions (2%) and 1 non-Q-wave myocardial infarction (1%) occurred. Revascularization of a treated lesion was undertaken in 15 patients (15%) because of clinical restenosis. Three patients (3%) underwent revascularization of new lesions, and 1 of these required coronary artery bypass graft. At the end of follow-up, 6 patients (6%) presented stable class II angina.

The event-free survival curves (all-cause mortality, infarction, and all revascularizations) are shown in the Figure. The curves for the RES and PES groups were similar and significantly better than the group treated with bare metal stenting. Table 5 shows the rate of repeat interventions due to restenosis by lesion type. Given that the 2 groups had different rates of statin treatment prior to the procedure, that is, those treated with bare metal stents were less exposed to statins, the influence of baseline treatment on incidence of revascularization of the treated lesion in this group was analyzed, but no significant differences were found (16% without statins, 14% with statins).

## DISCUSSION

The large studies done so far with RES and PES have only assessed lesions with slight or moderate risk of restenosis. Patients with lesions less than 30 mm, total obstructions, ostial lesions, lesions requiring stents with diameters less than 2.5 mm or in-stent res-

tenosis have been excluded. In these types of lesion, the effectiveness of drug-eluting stents is not completely known, although series have been published that suggest a good outcome.<sup>8-16</sup>

Drug-eluting stents may be most beneficial in these types of lesion because clinical restenosis with bare metal stents is high (10%-30%),<sup>17-28</sup> but studies have yet to be done that compare the efficacy and safety of the 2 types of drug-eluting stent. Clinically relevant differences in the outcomes of the 2 types of stent, if they do exist, would be more readily detected in high-risk lesions.

We therefore undertook this study in which we compared 3 types of treatment for the same lesion profile (diffuse lesions, lesions in small vessels, complete occlusion, and in-stent restenosis). The groups were consecutive because RES and PES were not introduced at the same time. The clinical and angiographic characteristics of the patients were very similar. The only difference of note was less in-stent restenosis in the PES group because RES had been introduced before study of the PES group, thus notably reducing in-stent restenosis. The lower incidence of restenosis in the group with bare metal stents compared to the RES group can be explained by a greater tendency for these patients to be referred for bypass surgery when drug-eluting stents were not available or for balloon-only treatments, which were more common at the time. These, then, were high-risk groups with a high rate of multilesion and multivessel revascularization and prior procedures.

### Stent Thrombosis

With regard to safety, the overall incidence of stent thrombosis was similar but thrombosis occurred at different times. The incidence of thrombosis with drug-eluting stents (2%) lies within acceptable ranges, bearing in mind that this was not a general series patients but rather a selected series with more complex lesions. One patient treated with PES had acute thrombosis and another treated with PES had late thrombosis. Both patients had something in common, namely, suboptimal flow in the diseased distal bed. Moreover, both patients underwent in-stent placement of drug-eluting stents. Abciximab was not used in the patient with acute thrombosis. The case of late thrombosis occurred 3 months after the procedure within 3 days of suspending treatment with clopidogrel, suggesting that a combined treatment of aspirin-clopidogrel for longer than 3 months, and maybe for as long as 6 months, is indicated in patients at highest risk (for example, very long or multiple stents or in-stent restenosis).

### Need for Repeat Revascularization

In high-risk patients, the rate of new revascularization in target lesions during follow-up for both groups

of drug-eluting stent is doubtlessly a spectacular finding. Likewise, the lower prevalence of symptoms of stable angina in the event-free patients is also an important finding. These results would be good even for a patient population with unselected lesions. The findings in the drug-eluting stent groups contrast with that observed in the group receiving bare metal stents, in which the need for repeat procedures was significantly higher.

The findings may appear too good—the differences are even higher than those reported in randomized trials and higher than the experience of other centers.<sup>2-14</sup> First, it could be argued that the lesions selected for treatment with drug-eluting stents might have been less complex, but the opposite is in fact true; there was a selection bias against the groups treated with drug-eluting stents. The patients who received such stents were those with the highest risk of restenosis and only those with lesions that met only 1 risk criterion (diffuse lesion or small vessel lesion, but not both) were given a bare metal stent. No patients receiving bare metal stents had complete occlusion or in-stent restenosis. Thus, the lesion profile might have been even more adverse in the groups who received drug-eluting stents.

Second, it might be argued that there is a bias toward lower repeat catheterization in the RES and PES groups, but the rate of repeat intervention in the group treated with bare metal stenting is just as low as that reported for other series of patients receiving bare metal stents.<sup>17-28</sup> Direct and independent evaluation of the clinical state of the patients at the end of follow-up confirms that this is the case, as only 2 patients in the RES group and 3 in the PES group presented class II stable angina at the end of follow-up. The real reasons for the lower rate of repeat intervention in the 3 groups compared to studies and series in other centers are as follows:

- In the randomized studies, it has been shown that angiographic follow-up increases the rate of revascularization with respect to clinical follow-up only.<sup>29</sup> Angiographic follow-up therefore does not reflect clinical impact, as angiography detects either clinically silent restenosis or restenosis leading to stable angina that is readily controlled by medical treatment. These findings suggest that revascularizations are performed that would never have been done in clinical practice. These observations are also applicable to studies with drug-eluting stents where many of the revascularization events coincide with when angiographic follow-up was done.<sup>30</sup>

- With regard to the experience of other centers, clinical cardiologists in Spain are not as predisposed to intervention as in other countries (particularly the United States and Western Europe).<sup>31</sup> This affirmation is supported by 2 observations. First, a significantly lo-

wer number of coronary angiograms are performed per million inhabitants and, second, stable angina or postsurgical angina figures notable less often among the indications for coronary angiography in Spain. This would explain why fewer repeat catheterizations are done in Spain in patients who only have class I or II stable angina that is controlled medically.<sup>31</sup>

## Antiplatelet Treatment

The duration of antiplatelet treatment varies according to the study and the stent used. Treatment lasted 6 months in studies with PES<sup>5-7</sup> and 2-3 months in studies with RES.<sup>2-4</sup> In our series, patients with RES were treated for 3 months and those with PES were treated for 6 months. A period of up to 6 months of treatment (given empirically) is probably recommended for both types of stent in patients with in-stent restenosis, a long stent, or multiple stents. The cases of late thrombosis described in the RES group support this approach, and we currently also take this approach.

## Limitations

This was an observational study that describes the results obtained in selected consecutive, series of patients. These patients were not randomized and angiographic monitoring was not done, which detracts from the findings of the study. Nevertheless, we stress that the study was done in the clinical practice setting. This study aimed to investigate and compare the impact that these new stents have within clinical practice on safety (incidence of thrombosis) and decreased need for repeat interventions, as well as on the clinical state of the patients at the end of a reasonable clinical follow-up. The direct and independent assessment of the clinical state of the patients at the end of follow-up confirms that the low need for repeat revascularization was realistic, as only 2 patients in the RES group and 3 in the PES group had class II stable angina.

A further limitation was that we did not systematically determine enzyme levels after the procedure in all patients (such determinations were only done in complicated cases), thus we have no information on the incidence of procedural necrosis in noncomplicated cases. In this respect, our group have recently assessed the incidence of elevated troponin I levels in consecutive series of patients treated with bare metal stents (200 patients) and RES (100 patients) in patients with noncomplicated lesions. We found no significant differences (15% vs 19%, respectively), despite a more adverse lesion profile in the group treated with RES.<sup>32</sup>

## CONCLUSIONS

Use of RES and PES in lesions at high risk of restenosis (diffuse lesions, vessel  $\leq 2.5$  mm, complete oc-

clusion and in-stent restenosis) seems to be as safe as bare metal stents and more effective. Given the aforementioned limitations of this study, larger series with randomized comparisons are needed to be more certain of these findings.

Models that predict restenosis are, however, difficult to construct,<sup>33</sup> so the main contraindication to more widespread use will probably continue to be the ever-present dispute about costs, at least for the foreseeable future.<sup>34</sup>

## REFERENCES

1. Serruys PW, Unger F, Sousa E, Jatene A, Bonnier HJRM, Schonberger JPAM, et al, for the ARTS study group. Comparison of coronary artery bypass surgery and stenting for the treatment of multivessel disease. *N Engl J Med*. 2001;344:1117-24.
2. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al, for the RAVEL study group. A randomized comparison of a sirolimus eluting stent with a standard stent for coronary revascularization. *N Engl J Med*. 2002;346:1773-80.
3. Moses J, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al, for the SIRIUS investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. *N Engl J Med*. 2003;349:1315-23.
4. Schofer J, Schluter M, Gershlick AH, Wijns W, García E, Schampaert E, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). *Lancet*. 2003;362:1093-9.
5. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, et al. Six and twelve month results from a randomized, double blind trial on a slow release paclitaxel eluting stent for de novo coronary lesions (TAXUS I). *Circulation*. 2003;107:38-42.
6. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. *N Engl J Med*. 2004;350:221-31.
7. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. One-year clinical results with the slow-release, polymer-based paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. *Circulation*. 2004;109:1942-7.
8. Degertekin M, Regar E, Tanabe K, Smits PC, van der Giessen WJ, Carlier SG, et al. Sirolimus eluting stent for treatment of complex in stent restenosis: The first clinical experience. *J Am Coll Cardiol*. 2003;41:184-9.
9. Tanabe K, Serruys PW, Grube E, Smits PC, Selbach G, van der Giessen WJ, et al. TAXUS III. In stent restenosis treated with stent based delivery of paclitaxel incorporated in a slow release polymer formulation. *Circulation*. 2003;107:559-64.
10. Radke PW, Kobella S, Kaiser A, Franke A, Schubert D, Grube E, et al. Treatment of in-stent restenosis using a paclitaxel-eluting stent: acute results and long-term follow-up of a matched-pair comparison with intracoronary beta-radiation therapy. *Eur Heart J*. 2004;25:920-5.
11. Li SS, So YC, Wong CH, Yiu SF, Chan KT. Treatment of long, diffuse in-stent restenosis with sirolimus eluting stents. *J Invasive Cardiol*. 2004;16:81-3.
12. Hoyer A, Tanabe K, Lemos PA, Aoki J, Saia F, Arampatzis C, et al. Significant reduction in restenosis after the use of sirolimus-

- eluting stents in the treatment of chronic total occlusions. *J Am Coll Cardiol*. 2004;43:1954-8.
13. Lemos PA, Arampatzis CA, Saia F, Hoye A, Degertekin M, Tanabe K, et al. Treatment of very small vessels with 2.25-mm diameter sirolimus-eluting stents (from the RESEARCH registry). *Am J Cardiol*. 2004;93:633-6.
  14. Lemos PA, Serruys PW, van Domburg RT, Saia F, Arampatzis CA, Hoye A, et al. Unrestricted utilization of sirolimus eluting stents compared with conventional bare metal stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. *Circulation*. 2004;109:190-5.
  15. Ruiz-Nodar JM, Frutos A, Carrillo P, Morillas P, Valero R, Rodríguez JA, et al. Utilización del *stent* recubierto de rapamicina en la revascularización de lesiones complejas: estudio con seguimiento clínico y angiográfico. *Rev Esp Cardiol*. 2004;57:123-9.
  16. de la Torre Hernández JM, Burgos V, González-Enríquez S, Cobo M, Zueco J, Figueroa A, et al. *Stent* liberador de rapamicina en el tratamiento de lesiones coronarias con alto riesgo de reestenosis. Seguimiento clínico a 6 meses de los primeros 100 pacientes. *Rev Esp Cardiol*. 2004;57:116-22.
  17. Kastrati A, Elezi S, Dirschinger J, Hadamitzky M, Neumann FJ, Schomig A. Influence of lesion length on restenosis after coronary stent placement. *Am J Cardiol*. 1999;83:1617-22.
  18. Kobayashi Y, de Gregorio J, Kobayashi N, Akiyama T, Reimers B, Finci L, et al. Stented segment length as an independent predictor of restenosis. *J Am Coll Cardiol*. 1999;34:651-9.
  19. Doucet S, Schalg MJ, Vrolix MCM, Hilton D, Chenu P, de Bruyne B, et al. Stent placement to prevent restenosis after angioplasty in small coronary arteries. *Circulation*. 2001;104:2029-33.
  20. Kastrati A, Schomig A, Dirschinger J, Mehilli J, Dotzer F, von Welsch N, et al. A randomized trial comparing stenting with balloon angioplasty in small vessels in patients with symptomatic coronary artery disease. *Circulation*. 2000;102:2593-8.
  21. Koning R, Eltchaninoff H, Commeau P, Khalife K, Gilard M, Lipiecki J, et al. Stent placement compared with balloon angioplasty for small coronary arteries: In hospital and 6-month clinical and angiographic results. *Circulation*. 2001;104:1604-8.
  22. Moer R, Myreng Y, Moldstad P, Albertsson P, Gunnes P, Lindvall B, et al. Stenting in small coronary arteries (SISCA) trial. A randomized comparison between balloon angioplasty and the heparin-coated beStent. *J Am Coll Cardiol*. 2001;38:1598-603.
  23. García E, Gómez-Recio M, Moreno R, Pasalodos J, Bethancourt A, Zueco J, et al. Stent reduces restenosis in small vessels. Results of the RAP study [abstract]. *J Am Coll Cardiol*. 2001;37:32-4.
  24. Rubartelli P, Niccoli L, Verna E, Giachero C, Zimarino M, Fontanelli A, et al. Stent implantation versus balloon angioplasty in chronic coronary occlusions: Results from the GISSOC trial. *J Am Coll Cardiol*. 1998;32:90-6.
  25. Buller CE, Dzavik V, Carere RG, Mancini GBJ, Barbeau G, Lazam C, et al. for the TOSCA investigators. Primary stenting versus balloon angioplasty in occluded coronary arteries. The total occlusion study of Canada (TOSCA) *Circulation*. 1999;100:236-42.
  26. Sievert H, Rohde S, Utech A, Schulze R, Scherer D, Merle H, et al. Stent or angioplasty after recanalization of chronic coronary occlusions ? The SARECCO trial. *Am J Cardiol*. 1999;84:386-90.
  27. Lotan C, Rozenman Y, Hendler A, Turgeman Y, Ayzenberg O, Beyar R, et al. Stents in total occlusion for restenosis prevention. The multicentre randomized STOP study. *Eur Heart J*. 2000;21:1960-6.
  28. Alfonso F, Zueco J, Cequier A, Mantilla R, Bethencourt A, López-Mínguez JR, et al. for the RIBS study. A randomized comparison of repeat stenting with balloon angioplasty in patients with in-stent restenosis. *J Am Coll Cardiol*. 2003;42:796-805.
  29. Ruygrok PN, Melkert R, Morel MA, Ormiston JA, Bär FW, Fernández-Avilés F, et al. Does angiography six months after coronary intervention influence management and outcome? *J Am Coll Cardiol*. 1999;34:1507-11.
  30. Hill RA, Dundar Y, Bakhai A, Dickson R, Walley T. Drug-eluting stents: an early systematic review to inform policy. *Eur Heart J*. 2004;25:902-19.
  31. López-Palop R, Moreu J, Fernández-Vázquez F, Hernández Antolín R. Registro Español de Hemodinámica y Cardiología Intervencionista. XIII Informe Oficial de la Sección de Hemodinámica y Cardiología Intervencionista de la Sociedad Española de Cardiología (1990-2003). *Rev Esp Cardiol*. 2004;57:1076-89.
  32. de la Torre Hernández JM, Burgos V, Pérez T, Sainz-Laso F, Figueroa A, Zueco J, et al. Respuesta inflamatoria tras implante de *stents* convencionales y *stents* de rapamicina: implicaciones pronósticas [abstract]. *Rev Esp Cardiol*. 2004;57 Supl 2:166.
  33. Singh M, Gersh BJ, McClelland RL, Ho KKL, Willerson JT, Penny WF, et al. Clinical and Angiographic Predictors of Restenosis After Percutaneous Coronary Intervention: Insights From the Prevention of Restenosis With Tranilast and Its Outcomes (PRESTO) Trial. *Circulation*. 2004;109:2727-31.
  34. Colombo A, Iakovou I. Drug-eluting stents: the new gold standard for percutaneous coronary revascularisation. *Eur Heart J*. 2004;25:895-7.